Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

ARGENX SE

CIK 1697862Updated Nov 16, 2026

Name history
argenx N.V · through Apr 21, 2017

ARGNF price & chart

Provider market data

Loading TradingView…

OTC:ARGNF on TradingView ↗

TradingView · Data may be delayed

About the company

argenx is the immunology innovation company, focused on turning immunology breakthroughs into medicines for patients. The company seeks novel biology wherever it emerges, co-creating with academic researchers through its Immunology Innovation Program (IIP) and investing in promising science, to develop treatments for people living with underserved diseases. By advancing molecules with the potential to reach multiple diseases and patient populations, argenx is building a world-class portfolio. This approach produced the first approved antibody fragment targeting the neonatal Fc receptor (FcRn) and today powers a growing pipeline of early and late-stage programs across several therapeutic areas. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

6-K · 2026-11-09 · 0001104659-26-124180

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Seeking Alpha

Recent filings

  1. 6-K filing

    6-K · 2026-11-09 · 0001104659-26-124180

  2. 6-K filing

    6-K · 2026-11-09 · 0001104659-26-124060

  3. SCHEDULE 13G/A - filed by FMR LLC regarding ARGENX SE

    SCHEDULE 13G/A · 2026-11-05 · 0000315066-26-002690

  4. 6-K filing

    6-K · 2026-10-22 · 0001697862-26-000034

  5. 6-K filing

    6-K · 2026-10-19 · 0001104659-26-116751

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-10-08 · 0001104659-26-114491

  2. 6-K filing

    6-K · 2026-09-29 · 0001104659-26-111631

  3. 6-K filing

    6-K · 2026-08-27 · 0001140361-26-034700

  4. 6-K filing

    6-K · 2026-08-17 · 0001104659-26-097589

  5. 6-K filing

    6-K · 2026-08-03 · 0001104659-26-089796

Financials

FY 2025 · USD
Revenue— · FY 2025
Net income1,292,035,000USD · FY 2025
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

Assets—USD · FY 2025
Cash— · FY 2025
Operating income1,053,806,000USD · FY 2025
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

Diluted EPS19.57USD per share · FY 2025
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ2 2020FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossUSD—1,292,035,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

833,040,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

-295,053,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-709,594,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForCurrentTaxOfPriorPeriodUSD—-13,224,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

383,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

2,080,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-12,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesUSD—-12,390,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

-7,644,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

4,411,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

677,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

AdjustmentsForSharebasedPaymentsUSD—248,079,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

235,179,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

232,974,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

157,026,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseUSD——1,055,337,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

711,905,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

472,132,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD—254,855,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

-7,801,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

37,515,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

24,141,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

InterestPaidClassifiedAsOperatingActivitiesUSD—900,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

392,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

211,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

851,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD—4,107,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

7,638,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

3,801,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

4,165,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD—105,515,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

66,500,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

43,000,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

102,986,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ProceedsFromIssuingShares—
Source

6-K · 2020-07-31 · 0001558370-20-008842

As of 2020-05-29

————

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Cost of Goods and Services Sold—
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

—
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

—
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

—
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

Selling, General and Administrative ExpenseUSD1,367,057,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

1,055,337,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

——
Additional Financial Items
ApplicableTaxRatenumber——0.26
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

0.26
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

BasicEarningsLossPerShareUSD per share21.08
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

13.92
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

-5.16
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-13.05
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

CurrentTaxExpenseIncomeUSD351,264,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

53,462,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

9,592,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-27,162,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

DepreciationRightofuseAssetsUSD10,441,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

5,759,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

3,846,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

2,949,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

DilutedEarningsLossPerShareUSD per share19.57
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

12.78
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

-5.16
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-13.05
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

EmployeeBenefitsExpenseUSD889,087,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

735,908,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

529,377,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

396,750,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD128,000,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

147,000,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

164,000,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

120,200,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedUSD——40,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

21,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedUSD——1,517,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

732,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

FinanceCostsUSD4,082,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

2,464,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

906,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

3,906,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

FinanceIncomeUSD163,091,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

157,509,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

107,386,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

27,665,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseUSD—1,055,337,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

711,905,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

472,132,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

IncomeTaxExpenseContinuingOperationsUSD-13,428,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

-747,860,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

-9,443,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-19,720,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

InterestExpenseOnLeaseLiabilitiesUSD3,175,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

2,072,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

693,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

1,343,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

OtherOperatingIncomeExpenseUSD1,423,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

———
PostemploymentBenefitExpenseDefinedBenefitPlansUSD24,751,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

12,330,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

7,758,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

5,406,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ProfessionalFeesExpenseUSD238,228,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

170,215,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

108,820,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

—
ProfitLossAttributableToOwnersOfParentUSD1,292,035,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

833,040,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

-295,053,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-709,594,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ProfitLossBeforeTaxUSD1,278,607,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

85,180,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

-304,496,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-729,314,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ProfitLossFromOperatingActivitiesUSD1,053,806,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

-21,654,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

-425,049,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

-720,341,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseUSD1,364,132,000
Source

20-F · 2026-03-19 · 0001697862-26-000032

2025-01-01 to 2025-12-31

983,423,000
Source

20-F · 2025-03-20 · 0001697862-25-000024

2024-01-01 to 2024-12-31

859,492,000
Source

20-F · 2024-03-21 · 0001558370-24-003665

2023-01-01 to 2023-12-31

663,366,000
Source

20-F · 2023-03-16 · 0001558370-23-004027

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

tm2629301d1_ex99-1.htm · 6-K · 2026-11-09

Exhibit 99.1 argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies Consistent, clinically meaningful treatment effect in DM, demonstrating i…

6-K · 2026-11-09 · 0001104659-26-124180

Read attachment ↗
tm2629301d2_ex99-1.htm · 6-K · 2026-11-09

Exhibit 99.1 argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities Pairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biology Extends argenx’s immunology innovation to more patients, with the potential for oral and long-acting medicines Builds on more than two years of collaboration and investment; UNP to continue operating from Santa Cruz, California wit…

6-K · 2026-11-09 · 0001104659-26-124060

Read attachment ↗
tm2627805d1_ex99-1.htm · 6-K · 2026-10-19

Exhibit 99.1 argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DM Patient improvements observed as early as Week 4 and sustained through 52 weeks Late-breaking oral presentation on Wednesday, November 1…

6-K · 2026-10-19 · 0001104659-26-116751

Read attachment ↗
tm2627263d1_ex99-1.htm · 6-K · 2026-10-08

Exhibit 99.1 argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovati…

6-K · 2026-10-08 · 0001104659-26-114491

Read attachment ↗
tm2627263d1_ex99-2.htm · 6-K · 2026-10-08

Exhibit 99.2 argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Dat…

6-K · 2026-10-08 · 0001104659-26-114491

Read attachment ↗
tm2626570d1_ex99-1.htm · 6-K · 2026-09-29

Exhibit 99.1 argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term d…

6-K · 2026-09-29 · 0001104659-26-111631

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.